Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 2, 26 | Gallman Cari | officer: EVP, General Counsel | M-Exempt | 4,559 | — |
| Oct 2, 26 |
| Gallman Cari |
| officer: EVP, General Counsel |
| F-InKind |
| 2,332 @ $61.15 |
| $142.6K |
| Oct 2, 26 | Gallman Cari | officer: EVP, General Counsel | M-Exempt | 4,559 | — |
| Sep 30, 26 | Yale Phyllis R | director | A-Award | 561 | — |
| Sep 30, 26 | Samuels Theodore R. Ii | director | A-Award | 821 | — |
| Sep 30, 26 | Rice Derica W | director | A-Award | 621 | — |
| Sep 30, 26 | Mcmullen Michael R. | director | A-Award | 561 | — |
| Sep 30, 26 | Arduini Peter J | director | A-Award | 561 | — |
Stock news · updated daily
Bristol Myers Squibb & Co. (NYSE:BMY) stock is trading lower on Friday after the company reported one patient death in an investigational CD19-directed CAR T cell therapy trial.
Bristol Myers edges out AbbVie with a cheaper valuation and higher dividend yield, but pipeline execution, legacy drug declines and debt remain key risks.
[url="]Bristol Myers Squibb[/url] (NYSE: BMY) today announced disclosure of interim safety and efficacy results from the multiple sclerosis (MS) cohorts of the
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CARTCellTherapy--Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients.
NEW YORK--(BUSINESS WIRE)--Pathos AI, Inc., a clinical-stage AI and technology company advancing its own therapeutic pipeline of drugs, today announced the closing of a $237 million Series E financing round at a post-money valuation of approximately $3 billion. The financing was led by Bristol Myers Squibb (NYSE: BMY), alongside participation from existing investors. The capital raise reflects significant operational momentum driven by Pathos's proprietary AI platform, Foundry. Over the past se.
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM, “Tempus”) today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”), under which BMS will license multimodal oncology data from Tempus through 2031 to support biological and clinical insight identification, novel drug target discovery and therapeutic development across its oncology portfolio. With this agreement, BMS significantly expands its strategic relationship with Tempus and becomes one of Tempus's largest li.
NEW YORK--(BUSINESS WIRE)--Pathos AI, a clinical-stage AI and technology company advancing its own therapeutic pipeline, today announced multi-year strategic collaborations with Bristol Myers Squibb (NYSE: BMY, “BMS”) and Tempus AI, Inc. (NASDAQ: TEM, “Tempus”) to build a specialized, curated dataset and agentic AI capabilities for Alzheimer's disease and other neurological conditions. BMS also leads Pathos's Series E financing and gains access to Pathos Foundry across its broader R&D portf.
Bristol Myers, SystImmune drug cuts breast cancer progression risk in study
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Jul 30, 2026 | 1.60 | 2.04 | Beat 27.5% | $12.97B |
| Apr 30, 2026 | 1.42 | 1.58 | Beat 11.3% | $11.49B |
| Feb 5, 2026 | 1.23 | 1.26 | Beat 2.4% | $12.50B |
| Oct 30, 2025 | 1.52 | 1.63 | Beat 7.2% | $12.22B |
| Jul 31, 2025 | 1.09 | 1.46 | Beat 33.9% | $12.27B |
| Apr 24, 2025 | 1.49 | 1.80 | Beat 20.8% | $11.20B |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4 | Oct 5, 2026 | 2026-10-05 16:18:59 | View |
| 4 | Oct 2, 2026 | 2026-10-02 16:26:53 | View |
| 4 | Oct 2, 2026 | 2026-10-02 16:25:51 | View |
| 4 | Oct 2, 2026 | 2026-10-02 16:24:53 | View |
| 4 | Oct 2, 2026 | 2026-10-02 16:23:20 | View |
| 4 | Oct 2, 2026 | 2026-10-02 16:22:09 | View |
| 4 | Sep 10, 2026 | 2026-09-10 16:37:19 | View |
| 144 | Sep 9, 2026 | 2026-09-09 10:27:54 | View |
| 4 | Sep 3, 2026 | 2026-09-03 16:12:26 | View |
| 4 | Aug 26, 2026 | 2026-08-26 16:17:45 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | BMY | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 13.6x | 12.0x · sector 20.7x | Discount |
| Forward P/E (FY26E) | 9.7x | EPS est. 6.34 | Discount |
| Price / Book | 5.6x | 5.1x | In line |
| Price / Sales | 2.6x | 2.7x | In line |
| EV / EBITDA | 9.5x | 16.8x | Discount |
| Return on equity | 46.8% | — | Top tier |
| Gross margin | 70.2% | 75.0% | In line |
| Debt / Equity | 1.93 | 1.93 | Levered |
| Piotroski / Altman Z | 7/9 | Z 2.68 | Grey zone |
Discounted cash flow model
Current price $61.53
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 13, 26 | Wells Fargo | maintain | Equal Weight | Equal Weight |
| Oct 8, 26 | Cantor Fitzgerald | maintain | Neutral | Neutral |
| Oct 7, 26 | Morgan Stanley | maintain | Underweight | Underweight |
| Oct 5, 26 | Leerink Partners | downgrade | Outperform | Market Perform |
| Sep 16, 26 | Piper Sandler | maintain | Overweight | Overweight |
| Sep 10, 26 | HSBC | maintain | Hold | Hold |
| Aug 5, 26 | Argus Research | upgrade | Hold | Buy |
| Aug 3, 26 | Citigroup | maintain | Neutral | Neutral |
| Jul 31, 26 | Guggenheim | maintain | Buy | Buy |
FY2025 · 10-K disclosure
FY2025 · 10-K disclosure
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 51.21 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 81.95 | Oscillator | Sell |
| Williams %R (14) | -27.69 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.42 (Hist 0.48) | Oscillator | Buy |
| Average Directional Index (14) | 17.92 (+DI 28.5 / -DI 21.2) | Trend | Neutral |
| EMA 20 | 60.88 | MA | Buy |
| SMA 20 | 60.43 | MA | Buy |
| EMA 50 | 61.73 | MA | Sell |
| SMA 50 | 63.20 | MA | Sell |
| SMA 200 | 59.81 | MA | Buy |